The Department of Health – Abu Dhabi (DoH) and Sanofi have signed a memorandum of understanding (MoU) to bolster vaccine development by leveraging local health-tech ecosystems and research infrastructure.
The MoU was signed at the BIO International Convention 2025 in Boston, in the US state of Massachusetts.
Go deeper with GlobalData
Both parties will focus on streamlining regulatory procedures, improving manufacturing readiness and facilitating knowledge exchange between regional and global experts.
The initiative aligns with Abu Dhabi’s vision to become an epicentre for bio and pharmaceutical innovation while promoting healthcare solutions powered by advanced technologies.
The alliance aims to advance clinical research and development (R&D) planning, improve resource allocation and set foundational funding terms that contribute to resilient healthcare systems.
These efforts are expected not only to benefit patients within Abu Dhabi but also extend quality care globally.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataDoH health life sciences sector executive director Dr Asma Al Mannaei stated: “DoH is partnering with Sanofi to expedite the development of new global vaccines. This initiative aims to shorten the timeline from early research to public availability by utilising advanced technologies, real-time data analysis and conducting parallel clinical trial phases.
“By combining Sanofi’s global scientific expertise with Abu Dhabi’s state-of-the-art infrastructure, we set new benchmarks for resilience, innovation and international partnerships.”
A delegation led by DoH is on a mission to the US from 15 June to 21 June 2025.
It will take part in 20 strategic meetings focused on knowledge sharing and exploring investment prospects that could further propel advanced health solutions’ adoption rates.
Sanofi Vaccines Greater Gulf general manager Baptiste de Clarens stated: “The MoU signed with the Department of Health – Abu Dhabi marks an encouraging step towards advancing global health security while reflecting our shared interest in addressing global health challenges through scientific partnership.”
Sanofi recently agreed to purchase Blueprint Medicines at an equity valuation of $9.1bn in a strategic move to strengthen its portfolio in the immunology domain with the addition of therapies for rare diseases.
